x
- Industry: Healthcare Payers
- Study Type: Payer and pricing assessment for a novel Hemophilia A Therapy
- Client: A leading Healthcare Consultancy Firm
Background & Key Objectives
- To assess the market opportunity for a novel Hemophilia A therapy in order to facilitate their discussions with national/regional payers across USA and EU5.
- To seek input on target product profiles and requisite data of interest and overall opinion on value based agreements.
Methodology & Approach
- Unimrkt conducted the assessment in two stages – Stage 1 of desk research and stage 2 of primary research with the target groups.
- Desk Research
- Unimrkt reviewed clinical guidelines in the USA and EU5 and analyzed the trends in actual clinical practice, primarily where differing from the clinical guidelines
- Primary Research
- Overall structure, and differentiating factors accounted for Rare disease products
- Product and pricing evaluation factors by HTA bodies like NICE, IQWiG, HAS, commercial payers, CMS, etc.
- Pricing structure of current standard of care product in the Hemophilia A care
- We conducted telephonic interviews with the USA & EU5 countries payers.
- Sample size: Total 150 interviews with payers; 30 payers in each of the countries (USA -30, EU5 countries - 120)
Our Solution
- Unimrkt developed the KIQs, programmed the survey in ConfirmIT and engaged in primary research with relevant payers to explore:
- Importance of a novel agent for Hemophilia A with the payers
- Likely pricing scales to be accepted
- Type of contract agreements finalized between payers and the manufacturers
- Access hurdles and restrictions at different price points
- Final data was shared in the form of data tables, cross tabs, top line analysis in client provided MS PPT template